Evelo Biosciences, Inc.

EVLO

US2997342025

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:00:06 28/06/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	-50.00%		-99.83%	-99.84%

02/05	North American Morning Briefing : Stock Futures -2-	DJ
25/04	North American Morning Briefing : More Tech -2-	DJ

Evelo Biosciences, Inc. Announces Simba Gill to Remain in Position as CEO

February 01, 2023 at 06:00 pm IST

Evelo Biosciences, Inc. announced that the Company's Board of Directors has asked Simba Gill to remain in his position as CEO at this time, and the Company has halted the search for his successor.

Latest news about Evelo Biosciences, Inc.

North American Morning Briefing : Stock Futures -2-	02/05	DJ
North American Morning Briefing : More Tech -2-	25/04	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04	DJ
North American Morning Briefing : Focus Turns to -2-	04/04	DJ
North American Morning Briefing : Stocks Set for -2-	28/03	DJ
North American Morning Briefing : Investors -2-	21/03	DJ
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	14/12	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	11/12	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	11/12	CI
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	21/11	CI
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	21/11	CI
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	21/11	CI
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	18/23/18	MT
Sector Update: Health Care Stocks Retreat in Late Afternoon	18/23/18	MT
Sector Update: Health Care	18/23/18	MT
Top Midday Decliners	17/23/17	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	17/23/17	MT
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	17/23/17	MT
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17/23/17	CI
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	10/23/10	MT
Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating	26/23/26	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	21/23/21	MT
Evelo Biosciences Signs Termination Agreement for Cambridge Office, Laboratory Space; Shares Up Premarket	21/23/21	MT

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EVELO BIOSCIENCES, INC.	-99.84%	1.9K
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs